Quality of life and systemic comorbidities in patients with ophthalmic disease

Aim: To ascertain the effect of serious systemic comorbidities upon the quality of life of patients with ophthalmic diseases. Methods: Time tradeoff utility values were obtained in consecutive ophthalmic patients who presented with ocular disease. Multivariate analysis was undertaken to evaluate whether the systemic comorbidities of diabetes mellitus, heart disease, cancer, cerebrovascular accident, and/or renal failure requiring dialysis influenced ocular utility values. Results: Among the 390 patients with ocular diseases studied, 250 had the systemic comorbidities of diabetes mellitus, heart disease, cancer, stroke, and/or renal failure requiring dialysis, while 140 lacked these comorbidities. There was no statistically significant difference (p = 0.091) between the comorbidity and no comorbidity groups in self assessed quality of life as measured by ocular utility values after taking into account potentially confounding variables. Conclusions: In patients with ocular disease, ocular utility values related to the visual loss do not appear to be affected by the presence of select, concomitant, serious systemic diseases. Thus, visual loss seems to cause a similar diminution in self assessed quality of life in those who do and do not have serious associated systemic comorbidities. This information has important implications for the calculation of cost effective analyses.

[1]  G. Brown,et al.  Utility values and age-related macular degeneration. , 2000, Archives of ophthalmology.

[2]  H. Davies,et al.  Reviewing audit: barriers and facilitating factors for effective clinical audit , 2000, Quality in health care : QHC.

[3]  Gary C. Brown,et al.  Cost-Effectiveness of Treatment for Threshold Retinopathy of Prematurity , 1999, Pediatrics.

[4]  G C Brown,et al.  Health care in the 21st century: evidence-based medicine, patient preference-based quality, and cost effectiveness. , 2000, Quality management in health care.

[5]  G. Brown,et al.  Utility values and diabetic retinopathy. , 1999, American journal of ophthalmology.

[6]  Redelmeier Da,et al.  A clinician's guide to utility measurement. , 1995 .

[7]  W. Tasman,et al.  Incremental cost effectiveness of laser photocoagulation for subfoveal choroidal neovascularization. , 2000, Ophthalmology.

[8]  G. Brown,et al.  Vision and quality-of-life. , 1999, Transactions of the American Ophthalmological Society.

[9]  G. Brown,et al.  Quality of life associated with diabetes mellitus in an adult population. , 2000, Journal of diabetes and its complications.

[10]  DIFFERENCE BETWEEN OPHTHALMOLOGISTS' AND PATIENTS' PERCEPTIONS OF QUALITY OF LIFE ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION , 2000 .

[11]  A S Detsky,et al.  A clinician's guide to utility measurement. , 1995, Primary care.

[12]  R L Kane,et al.  Methodology for measuring health-state preferences--I: Measurement strategies. , 1989, Journal of clinical epidemiology.

[13]  G. Brown,et al.  Evidence-based medicine and cost-effectiveness. , 1999, Journal of health care finance.

[14]  D. Feeny,et al.  Utilities and Quality-Adjusted Life Years , 1989, International Journal of Technology Assessment in Health Care.

[15]  Adele Goldberg,et al.  Measurement Strategies , 1996, ECOOP.

[16]  A S Detsky,et al.  Primer on Medical Decision Analysis: Part 3—Estimating Probabilities and Utilities , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.

[17]  G. Brown,et al.  Difference between ophthalmologists' and patients' perceptions of quality of life associated with age-related macular degeneration. , 2000, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.